Phase 1 Trial of CUDC-907
Contact
Description
This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certain proteins in tumor cells; these proteins may be important in the growth of some cancers. The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents. This study will also look at the levels of CUDC-907 in the blood over time after a dose.
Eligibility and criteria
What to expect
This study will enroll male and female patients who are between 1 and 21 years of age and who have relapsed or refractory solid tumor, brain tumor, or lymphoma. Subjects will take CUDC-907 capsules by mouth. CUDC-907 must be taken within 30 minutes of a meal. Subjects will be asked to keep a drug diary and write down information about the study drug.
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.